ClinicalTrials.gg
CompletedNCT01350115Updated Oct 19, 2015Results posted

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

A Phase 2 interventional study of LDE225 and Placebo in Basal Cell Carcinoma, Gorlin Syndrome and Nevoid Basal Cell Carcinoma Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-19.

Primary conditionBasal Cell Nevus SyndromeRegistry: Carcinoma, Basal CellReclassifiedWhy we changed it
Registry
Carcinoma, Basal Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Basal Cell Nevus Syndrome
Why
  1. The study's listed conditions name Basal Cell Nevus Syndrome, a narrower term within Carcinoma, Basal Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This was a phase II, double-blind, randomized, proof-of-concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with NBCCS. This was an exploratory study designed to demonstrate preliminary efficacy of LDE225 in this indication. This study included a Screening period of approximately 4 weeks, treatment period duration of 12 weeks with initial follow-up of approximately 6-8 weeks followed by a long-term follow-up period.

02

Conditions studied

  • Basal Cell Carcinoma
  • Gorlin Syndrome
  • Nevoid Basal Cell Carcinoma Syndrome

Browse trials for

Keywords

  • Basal Cell Carcinoma
  • Gorlin Syndrome,
  • Gorlin-Goltz Syndrome,
  • Basal Cell Nevus Syndrome,
  • Nevoid Basal Cell Carcinoma Syndrome,
  • Basal Cell Carcinoma Nevus Syndrome
  • Smo inhibitor,
  • Hedgehog pathway inhibitor
  • BCCs
03

In context

Basal Cell Nevus Syndrome Reclassified

35 studies on the registry are indexed under Basal Cell Nevus Syndrome; 4 are open to participants now.

This study's enrollment of 10 is below the median of 24 across 25 interventional studies indexed under Basal Cell Nevus Syndrome.

Browse Basal Cell Nevus Syndrome studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Basal Cell Nevus Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma, Basal Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with multiple basal cell carcinomas (at least two) and typical presentation of NBCCS.
  • Female patients must be women of non- (WONCBP).

Exclusion criteria

Exclusion Criteria:

  • Use of any topical treatment to treat BCCs, including prescription and over the counter in the 4 weeks prior to first dose of study drug.
  • Use of photodynamic therapy (PDT), radiation or systemic treatment known to affect BCCs or neoplasm in the 12 weeks prior to first dose of study drug.
  • Patients receiving medications that are recognized to cause rhabdomyolysis or patients with a prior history of rhabdomyolysis.
  • Patients with a confirmed diagnosis of locally advanced or BCC.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    LDE225

    Participants received 400 mg once daily.

    Drug: LDE225

  • Placebo comparator
    Placebo

    Participants received matching placebo.

    Drug: Placebo

Interventions

  • DrugLDE225

    supplied as 100 mg capsules

  • DrugPlacebo

    supplied in capsules

06

What researchers measure

Primary outcomes

  1. Clinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs)

    The clinical response of the main target (and secondary target, as appropriate) BCC(s) to treatment was evaluated using the following 6-point scale comparing the assessment at the visit to the clinical presentation at Baseline: 0 = Worsening, 1 = No change, 2 = Slight clearance (1-25% improvement), 3 = Moderate clearance (26-75% improvement), 4 = Marked clearance (76-99% improvement),5 = Complete clearance (100% improvement) Complete clearance was defined as no clinical residual signs of carcinoma, as evaluated by the Investigator at a post-Baseline visit, with the exception of post-inflammatory changes such as minimal residual erythema or residual hyper-pigmentation or hypo-pigmentation or residual scarring.

    Time frame: Day 113

Secondary outcomes

  1. Histological Clearance Assessment of Main Target BCCs

    The main (and secondary, if appropriate) target BCC tumor area(s) was/were excised surgically and sent to a central laboratory for histological examination.

    Time frame: day 113

  2. Measure: Disease Burden by BCC Tumor Counts

    BCC tumor counts were performed separately for five body regions: head and neck, trunk back, trunk front (including axillae and groin), upper extremities and lower extremities (including buttocks). During the counting, the BCC tumors, were categorized upon inspection by their longest diameter measurement (\<10 mm, 10-19 mm, 20-29 mm, and \>+30mm), and also by the type of BCC (superficial, nodular, other). The counts for all of the BCC type and size categories were determined (or estimated if many small lesions) for each body region. The body region counts were summated to provide the overall BCC tumor count.

    Time frame: Baseline, day 85, and day 113

07

Results

Posted Oct 19, 2015

Participant flow

Core Study (All Patients)
Participant flow — Core Study (All Patients)
MilestoneLDE225Placebo
Started82
Safety anlysis set82
Pharmacodynamic set72
Completed82
Not completed00
Long Term Follow-Up (All Patients)
Participant flow — Long Term Follow-Up (All Patients)
MilestoneLDE225Placebo
Started82
Completed70
Not completed12
Withdrew: Lost to follow-up01
Withdrew: Adverse event01
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryClinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs)

The clinical response of the main target (and secondary target, as appropriate) BCC(s) to treatment was evaluated using the following 6-point scale comparing the assessment at the visit to the clinical presentation at Baseline: 0 = Worsening, 1 = No change, 2 = Slight clearance (1-25% improvement), 3 = Moderate clearance (26-75% improvement), 4 = Marked clearance (76-99% improvement),5 = Complete clearance (100% improvement) Complete clearance was defined as no clinical residual signs of carcinoma, as evaluated by the Investigator at a post-Baseline visit, with the exception of post-inflammatory changes such as minimal residual erythema or residual hyper-pigmentation or hypo-pigmentation or residual scarring.

Time frame:
Day 113
Reported as:
Number · Participants
Clinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs)
ParticipantsLDE225Placebo
Complete Clearance (100% Improvement)30
Marked Clearance (76-99% Improvement)30
Moderate Clearance (26-75% improvement)10
Slight Clearance (1-25%)01
Worsening01
SecondaryHistological Clearance Assessment of Main Target BCCs

The main (and secondary, if appropriate) target BCC tumor area(s) was/were excised surgically and sent to a central laboratory for histological examination.

Time frame:
day 113
Reported as:
Number · Percentage of participants
Histological Clearance Assessment of Main Target BCCs
Percentage of participantsLDE225Placebo
Histological clearance570
Complete clinical (up to day 85) & histological140
Complete clinical (up to day 113) & histological290
SecondaryMeasure: Disease Burden by BCC Tumor Counts

BCC tumor counts were performed separately for five body regions: head and neck, trunk back, trunk front (including axillae and groin), upper extremities and lower extremities (including buttocks). During the counting, the BCC tumors, were categorized upon inspection by their longest diameter measurement (\<10 mm, 10-19 mm, 20-29 mm, and \>+30mm), and also by the type of BCC (superficial, nodular, other). The counts for all of the BCC type and size categories were determined (or estimated if many small lesions) for each body region. The body region counts were summated to provide the overall BCC tumor count.

Time frame:
Baseline, day 85, and day 113
Reported as:
Number · Number of BCC tumors
Measure: Disease Burden by BCC Tumor Counts
Number of BCC tumorsLDE225Placebo
Baseline566510
Day 85341571
Day 113309619

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225 - Core—0/8 (0%)7/8 (87.5%)
Placebo - Core—1/2 (50%)1/2 (50%)
LDE225 - Long Term Follow-up—1/8 (12.5%)2/8 (25%)
Placebo - Long Term Follow-up—0/2 (0%)0/2 (0%)
Most frequent serious events
Most frequent serious events
EventLDE225 - CorePlacebo - CoreLDE225 - Long Term Follow-upPlacebo - Long Term Follow-up
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/81/20/80/2
CellulitisInfections and infestations0/80/21/80/2
Most frequent other events
Showing 10 of 37
Most frequent other events
EventLDE225 - CorePlacebo - CoreLDE225 - Long Term Follow-upPlacebo - Long Term Follow-up
Eyelid irritationEye disorders0/81/20/80/2
ConstipationGastrointestinal disorders0/81/20/80/2
Postoperative wound infectionInfections and infestations0/81/20/80/2
Muscle spasmsMusculoskeletal and connective tissue disorders3/81/20/80/2
OsteoarthritisMusculoskeletal and connective tissue disorders0/81/20/80/2
NauseaGastrointestinal disorders2/80/20/80/2
FatigueGeneral disorders2/80/20/80/2
NasopharyngitisInfections and infestations2/80/20/80/2
Blood creatine phosphokinase increasedInvestigations2/80/20/80/2
HeadacheNervous system disorders2/80/20/80/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LDE225PlaceboTotal
Mean50.5 ± 9.9066 ± 2.0053.6 ± 10.95
Sex: Female, Male
Sex: Female, Male(Participants)LDE225PlaceboTotal
Female404
Male426
08

Study locations

6 sites
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Markham, Ontario L3P 1A8, Canada
  • Novartis Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2K 4L5, Canada
  • Novartis Investigative Site
    Kiel, 24105, Germany
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2011
First posted
May 9, 2011
Start
Apr 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Oct 19, 2015
Last update
Oct 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01350115
Responsible party
Sponsor
First posted
May 9, 2011
Start date
Apr 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Oct 19, 2015
Last update
Oct 19, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion